Target Name: MIR200B
NCBI ID: G406984
Review Report on MIR200B Target / Biomarker Content of Review Report on MIR200B Target / Biomarker
MIR200B
Other Name(s): MIRN200B | microRNA 200b | hsa-mir-200b | mir-200b | MicroRNA 200b | hsa-miR-200b-3p | hsa-miR-200b-5p

MIR200B: A Potential Drug Target and Biomarker

MIR200B, also known as MIRN200B, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and respiratory infections. MIR200B is a small molecule RNA (siRNA) that can interact with specific target genes and silence their expression, thereby inhibiting the activity of these genes. In this article, we will discuss the potential drug target of MIR200B, its potential as a biomarker, and its underlying molecular mechanisms.

Potential Drug Target of MIR200B

MIR200B has been shown to interact with multiple target genes across various organisms, including humans. One of the most well-studied targets of MIR200B is the nuclear factor of activating transcription factor 3 (NFAT), a transcription factor that plays a crucial role in the development and progression of many diseases, including cancer.

MIR200B has been shown to physically interact with the NFAT protein and prevent its phosphorylation, which is a critical step in the NFAT signaling pathway. This interaction between MIR200B and NFAT has been shown to inhibit the transcriptional activity of NFAT, leading to the downregulation of target genes.

In addition to its interaction with NFAT, MIR200B has also been shown to interact with other transcription factors, including transcription factor binding protein RNA (TF-RNA), erythropoietin gene-interacting protein 1 (HSF1), and nucleotide binding RNA-binding proteins (RBPs) and long non-coding RNAs (lncRNAs). These interactions indicate that MIR200B has broad application prospects in regulating gene expression.

Biomarker Potential of MIR200B

MIR200B has also been shown to serve as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and respiratory infections. One of the main advantages of MIR200B as a biomarker is its ability to be expressed and detected in a variety of biological samples, including blood, urine, and tissue samples.

Studies have shown that MIR200B can be used as a biomarker for several diseases, including cancer, neurodegenerative diseases, and respiratory infections. For example, MIR200B has been shown to be downregulated in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, MIR200B has been shown to be involved in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

MIR200B has also been shown to be involved in respiratory infections, such as pneumonia and asthma. Studies have shown that MIR200B can be expressed and detected in respiratory tract samples from patients with these diseases, and that it can inhibit the activity of bacteria and fungi that are causing these infections.

Molecular Mechanisms of MIR200B

MIR200B is a small molecule RNA that can interact with specific target genes and silence their expression. The molecular mechanisms underlying this interaction between MIR200B and its target genes are not yet fully understood, but they are likely related to the regulation of gene expression through the RNA interference pathway.

One of the key mechanisms by which MIR200B interacts with its target genes is through the inhibition of the activity of RNA interference (RNAi) machinery, which is responsible for double-stranded RNA-induced RNA silencing pathway. RNAi

Protein Name: MicroRNA 200b

The "MIR200B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR200B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21 | MIR210 | MIR210HG | MIR211 | MIR2110 | MIR2113 | MIR2114 | MIR2115 | MIR2116 | MIR2117 | MIR212 | MIR214 | MIR215 | MIR216A | MIR216B | MIR217 | MIR217HG | MIR218-1 | MIR218-2 | MIR219A1 | MIR219A2 | MIR219B | MIR22 | MIR221 | MIR222 | MIR223 | MIR224 | MIR2276 | MIR2277 | MIR2278 | MIR22HG | MIR2355 | MIR2392 | MIR23A | MIR23AHG | MIR23B | MIR23C | MIR24-1 | MIR24-2 | MIR2467 | MIR25 | MIR2681 | MIR2682 | MIR26A1 | MIR26A2 | MIR26B | MIR27A | MIR27B | MIR28 | MIR2861 | MIR2909 | MIR296 | MIR297 | MIR298 | MIR299 | MIR29A | MIR29B1 | MIR29B2 | MIR29B2CHG | MIR29C | MIR300 | MIR301A | MIR301B | MIR302A | MIR302B | MIR302C | MIR302D | MIR302E | MIR302F | MIR3059 | MIR3064 | MIR3065 | MIR3074 | MIR3085 | MIR30A | MIR30B | MIR30C1 | MIR30C2 | MIR30D | MIR30E | MIR31 | MIR3115